Compare PAA & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAA | GH |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 13.3B |
| IPO Year | N/A | 2018 |
| Metric | PAA | GH |
|---|---|---|
| Price | $21.37 | $93.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 20 |
| Target Price | $20.80 | ★ $117.80 |
| AVG Volume (30 Days) | ★ 2.9M | 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.82% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $7.33 | $29.73 |
| Revenue Next Year | $0.28 | $27.71 |
| P/E Ratio | $12.39 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $15.58 | $34.91 |
| 52 Week High | $21.43 | $120.74 |
| Indicator | PAA | GH |
|---|---|---|
| Relative Strength Index (RSI) | 73.67 | 36.44 |
| Support Level | $17.20 | $54.39 |
| Resistance Level | N/A | $115.77 |
| Average True Range (ATR) | 0.37 | 6.14 |
| MACD | 0.05 | -1.21 |
| Stochastic Oscillator | 89.68 | 19.25 |
Plains All American Pipeline LP through its subsidiaries, engages in the pipeline transportation, terminaling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates through two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, and barges or railcars. The NGL segment is involved in natural gas processing and NGL fractionation, storage, transportation, and terminalling. It generates the majority of its revenue from the Crude Oil segment.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.